Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophrenia

Griffiths, Kira, Smart, Sophie E. ORCID: https://orcid.org/0000-0002-6709-5425, Barker, Gareth J., Deakin, Bill, Lawrie, Stephen M., Lewis, Shon, Lythgoe, David J., Pardinas, Antonio F. ORCID: https://orcid.org/0000-0001-6845-7590, Singh, Krishna ORCID: https://orcid.org/0000-0002-3094-2475, Semple, Scott, Walters, James T.R. ORCID: https://orcid.org/0000-0002-6980-4053, Williams, Stephen R., Egerton, Alice and MacCabe, James H. 2023. Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophrenia. Schizophrenia Research 260 , pp. 152-159. 10.1016/j.schres.2023.08.020

PDF - Published Version Available under License Creative Commons Attribution. Download (759kB)

Abstract

Dysfunction of glutamate neurotransmission has been implicated in the pathophysiology of schizophrenia and may be particularly relevant in severe, treatment-resistant symptoms. The underlying mechanism may involve hypofunction of the NMDA receptor. We investigated whether schizophrenia-related pathway polygenic scores, composed of genetic variants within NMDA receptor encoding genes, are associated with cortical glutamate in schizophrenia. Anterior cingulate cortex (ACC) glutamate was measured in 70 participants across 4 research sites using Proton Magnetic Resonance Spectroscopy (1H-MRS). Two NMDA receptor gene sets were sourced from the Molecular Signatories Database and NMDA receptor pathway polygenic scores were constructed using PRSet. The NMDA receptor pathway polygenic scores were weighted by single nucleotide polymorphism (SNP) associations with treatment-resistant schizophrenia, and associations with ACC glutamate were tested. We then tested whether NMDA receptor pathway polygenic scores with SNPs weighted by associations with non-treatment-resistant schizophrenia were associated with ACC glutamate. A higher NMDA receptor complex pathway polygenic score was significantly associated with lower ACC glutamate (β = −0.25, 95 % CI = −0.49, −0.02, competitive p = 0.03). When SNPs were weighted by associations with non-treatment-resistant schizophrenia, there was no association between the NMDA receptor complex pathway polygenic score and ACC glutamate (β = 0.05, 95 % CI = −0.18, 0.27, competitive p = 0.79). These results provide initial evidence of an association between common genetic variation implicated in NMDA receptor function and ACC glutamate levels in schizophrenia. This association was specific to when the NMDA receptor complex pathway polygenic score was weighted by SNP associations with treatment-resistant schizophrenia.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Publisher:	Elsevier
ISSN:	0920-9964
Date of First Compliant Deposit:	31 October 2023
Date of Acceptance:	18 August 2023
Last Modified:	30 Jun 2024 23:18
URI:	https://orca.cardiff.ac.uk/id/eprint/163583

Actions (repository staff only)

Edit Item